➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Baxter
Medtronic
Harvard Business School
Express Scripts
McKesson

Last Updated: September 28, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR LYSODREN

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for LYSODREN

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00304070 ↗ Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical Tumor Active, not recruiting National Cancer Institute (NCI) Phase 3 2006-09-01 This phase III clinical trial is studying how well cisplatin-based chemotherapy and/or surgery works in treating young patients with stage I, stage II, stage III or stage IV adrenocortical cancer. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Giving chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving it after surgery may kill any tumor cells that remain after surgery.
NCT00304070 ↗ Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical Tumor Active, not recruiting Children's Oncology Group Phase 3 2006-09-01 This phase III clinical trial is studying how well cisplatin-based chemotherapy and/or surgery works in treating young patients with stage I, stage II, stage III or stage IV adrenocortical cancer. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Giving chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving it after surgery may kill any tumor cells that remain after surgery.
NCT00778817 ↗ IMC-A12 With Mitotane vs Mitotane Alone in Recurrent, Metastatic, or Primary ACC That Cannot Be Removed by Surgery Terminated National Cancer Institute (NCI) Phase 2 2008-12-01 This randomized phase II trial is studying mitotane and IMC-A12 to see how well they work compared with mitotane alone in treating patients with recurrent, metastatic, or primary adrenocortical cancer that cannot be removed by surgery. Drugs used in chemotherapy, such as mitotane, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as IMC-A12, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. It is not yet known whether mitotane is more effective with or without monoclonal antibody IMC-A12 in treating adrenocortical cancer.
NCT02057237 ↗ A Safety and Feasibility Study of Mitotane in Prostate Cancer Completed University Health Network, Toronto Phase 1 2013-09-01 1. The primary objective of this study is to assess the feasibility of treating patients with metastatic castration resistant prostate cancer with mitotane. Secondary objectives are to assess safety and tolerability as well as response rate of therapy 2. To assess the toxicity of Mitotane in men with HRPC 3. To assess the relationship between baseline serum adrenal androgens and their response to Mitotane
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for LYSODREN

Condition Name

Condition Name for LYSODREN
Intervention Trials
Stage IV Adrenocortical Carcinoma 2
Stage III Adrenocortical Carcinoma 2
ENSAT Stage III Adrenal Cortex Carcinoma 1
ENSAT Stage II Adrenal Cortex Carcinoma 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for LYSODREN
Intervention Trials
Carcinoma 3
Adrenocortical Carcinoma 3
Adrenal Cortex Neoplasms 2
Recurrence 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for LYSODREN

Trials by Country

Trials by Country for LYSODREN
Location Trials
United States 39
Canada 6
Brazil 2
Australia 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for LYSODREN
Location Trials
Michigan 2
Ohio 2
Illinois 2
Texas 2
California 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for LYSODREN

Clinical Trial Phase

Clinical Trial Phase for LYSODREN
Clinical Trial Phase Trials
Phase 3 2
Phase 2 1
Phase 1 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for LYSODREN
Clinical Trial Phase Trials
Terminated 1
Active, not recruiting 1
Completed 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for LYSODREN

Sponsor Name

Sponsor Name for LYSODREN
Sponsor Trials
National Cancer Institute (NCI) 2
European Network for the Study of Adrenal Tumors (ENS@T) 1
Amercian Australian Asian Adrenal Alliance (A5) 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for LYSODREN
Sponsor Trials
Other 5
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Harvard Business School
Express Scripts
Mallinckrodt
Johnson and Johnson
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.